Soligenix, Inc.
SNGXDrugs in Pipeline
6
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How SNGX's past catalysts played out
SGX301 (synthetic hypericin)
Cutaneous T-Cell Lymphoma
Hypericin
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
SGX942
Oral Mucositis
SGX201 (delayed release beclomethasone 17,21-dipropionate)
Enteritis
Dusquetide
Behçet Disease
Mechlorethamine Topical Gel
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SGX301 (synthetic hypericin) | Phase 3 | Cutaneous T-Cell Lymphoma | - | - |
Hypericin | Phase 3 | Cutaneous T-Cell Lymphoma/Mycosis Fungoides | - | - |
SGX942 | Phase 3 | Oral Mucositis | - | - |
SGX201 (delayed release beclomethasone 17,21-dipropionate) | Phase 2 | Enteritis | - | - |
Dusquetide | Phase 2 | Behçet Disease | - | - |
Mechlorethamine Topical Gel | Phase 2 | Cutaneous T-Cell Lymphoma/Mycosis Fungoides | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Soligenix, Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in Soligenix, Inc.'s (SNGX) pipeline across Phase 3, Phase 2. Its lead program is SGX301 (synthetic hypericin) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Soligenix, Inc.'s next FDA catalyst?→
Soligenix, Inc.'s (SNGX) next tracked catalyst is a Phase 3 expected July 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SNGX biotech catalysts?→
Add SNGX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Soligenix, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.